Daxor CorpDXR

Daxor’s Blood Volume Analysis metric has just been validated as uniquely accurate versus capillary leak indexes in new clinical data presented at SCCM 2026, according to the company’s official newsroom. The firm’s BVA kit is pitched as a precision tool for cardiologists and intensivists wrestling with sepsis, heart failure, and acute respiratory distress, where a wrong guess on intravascular volume can turn a treatment plan into a tragedy. The evidence is clinical, not financial, but the gap between the diagnostic promise and the issuer’s balance sheet remains the story most investors can actually read.

Officially, Daxor sells a medical device that measures blood volume using an indicator-dilution method, a technology that is neither new nor flashy but is clinically defensible. The firm markets the kit to high-volume cardiology centres, a customer segment that matters more for utilisation than for headline revenues in a small-cap medtech story. The website’s clinical applications page features John Jefferies M.D., MPH, FACC, FAHA, FAAP, FHFSA, FRCPE, whose credentials read like a medical alphabet soup designed to convince sceptics that the device is at least backed by someone who has survived several professional societies. The brochure art is vintage 1990s, which may explain why the firm’s evidence trail feels like a fax from the past decade rather than a modern filings portal.

Fiscal 2025 results are announced on the newsroom page alongside an image candidate stock chart and a management desks-style header, but the page contains no revenue, net income, EPS, operating cash flow, or free cash flow figures, so any claim about scale or momentum is speculation rather than fact. The firm’s Ohio cardiology centre expansion is real-it is named in the newsroom-but the release stops at the customer win and does not disclose contract size, device ASP, or utilisation data. The clinical evidence page links to a pilot study titled “Endothelial Dysfunction in Critically Ill Patients with Sepsis and COVID-19 Using the Albumin Transudation Rate,” which is peer-reviewed science, yet the page itself carries the same disclaimer as the contact page: the information is not a substitute for professional medical advice, a legalistic nod to the limits of the evidence presented.

If you want a chart route for DAXOR on TradingView, the issuer trades on the OTCQB under the symbol DXR, where the daily candlesticks reflect thin liquidity and price action driven more by newsflow than by deep order books. The chart is available at https://www.tradingview.com/symbols/OTCQB-DXR/ and is best viewed as a curiosity meter rather than a liquid market.

What changed this week: the SCCM 2026 clinical validation and the Ohio cardiology centre expansion are concrete, albeit non-financial, developments. What remains unproven: revenue scale, gross margin, operating cash generation, and any quantitative customer utilisation data. What would deepen the file next: an SEC 10-K or 10-Q filing with GAAP numbers, a segment disclosure, or a regulatory approval milestone such as FDA 510(k) clearance for a specific device model. Until then, the evidence trail is a series of clinical footnotes tethered to a thinly traded equity story whose market price is a better barometer of newsletter interest than of device sales.